Loading
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Previous close
$8.34
−$0.32 · -3.70%
Regular session · ET · Market data may be delayed.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Day range
Current $8.34
52-week range
Current $8.34
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
14
Overpriced
Sentiment
63
Bullish
Risk
63
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Day range
Current $8.34
52-week range
Current $8.34
Operating income
Net income
| Metric (CHF) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 686K CHF | — | — | — |
| Cost of goods sold | — | 52.08M CHF | — | — | — |
| Gross profit | — | −51.4M CHF | — | — | — |
| Research and development | 54.52M CHF | 52.08M CHF | 29.25M CHF | 22.22M CHF | 9.57M CHF |
| Selling, general, and administrative | 24.63M CHF | 21.81M CHF | 14.72M CHF | 6.74M CHF | 4.1M CHF |
| Operating expenses | 79.15M CHF | 21.81M CHF | 80.71M CHF | 32.38M CHF | 13.23M CHF |
| Interest income | 1.69M CHF | 2.17M CHF | 1.59M CHF | 126K CHF | 21K CHF |
| Interest expense | 795.55K CHF | 639K CHF | 1.46M CHF | 6.44M CHF | 5.12M CHF |
| Depreciation and amortization | 546K CHF | 406K CHF | 287K CHF | 299K CHF | 235K CHF |
| Operating income | −79.15M CHF | −73.2M CHF | −80.71M CHF | −32.38M CHF | −13.23M CHF |
| Net income | −94.51M CHF | −85.78M CHF | −88.8M CHF | −38.7M CHF | −18.55M CHF |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$36.75
340.65% upsideFunds reporting this stock among their holdings, ordered by reported position size.
ALPS Medical Breakthroughs ETFSBIO652.53K0.34%191.36M USD0.50%$55.04+2.03%
Virtus Biotech Clinical Trials ETFBBC247.8K0.60%41M USD0.65%$44.1456+2.08%
State Street SPDR S&P International Small Cap ETFGWX246.44K0.03%907.87M USD0.40%$45.56+0.93%
Fidelity Nasdaq Composite Index ETFONEQ217.81K—10.94B USD0.21%$107.81+0.63%
GlacierShares Nasdaq Iceland ETFGLCR59.31K4.15%1.42M USD0.95%$23.69+0.77%ALPS Medical Breakthroughs ETFSBIOVirtus Biotech Clinical Trials ETFBBCState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQGlacierShares Nasdaq Iceland ETFGLCRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
